Insulet Corporation $PODD Position Lessened by Integrated Advisors Network LLC

Integrated Advisors Network LLC lowered its position in Insulet Corporation (NASDAQ:PODD) by 41.9% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 26,729 shares of the medical instruments supplier’s stock after selling 19,238 shares during the quarter. Integrated Advisors Network LLC’s holdings in Insulet were worth $5,609,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently bought and sold shares of PODD. Larson Financial Group LLC raised its position in Insulet by 114.6% during the fourth quarter. Larson Financial Group LLC now owns 88 shares of the medical instruments supplier’s stock valued at $25,000 after acquiring an additional 47 shares in the last quarter. University of Texas Texas AM Investment Management Co. bought a new position in shares of Insulet during the 4th quarter valued at $26,000. Elyxium Wealth LLC bought a new position in shares of Insulet during the 4th quarter valued at $28,000. DV Equities LLC acquired a new stake in shares of Insulet in the 4th quarter valued at $28,000. Finally, MV Capital Management Inc. acquired a new stake in shares of Insulet in the 4th quarter valued at $29,000.

Key Headlines Impacting Insulet

Here are the key news stories impacting Insulet this week:

• Positive Sentiment: Insulet launched Omnipod 5 and Omnipod Discover in Spain, expanding access to its tubeless diabetes technology and supporting the company’s global growth story. Insulet launches Omnipod 5, Omnipod Discover in Spain
• Positive Sentiment: Deutsche Bank initiated coverage on Insulet with a Buy rating and a $190 price target, signaling Wall Street sees additional upside from the company’s tubeless insulin delivery franchise. Insulet (PODD): Deutsche Bank Initiates Coverage With a Buy and a $190 Target
• Neutral Sentiment: Zacks published a broader medical-stocks earnings preview, which does not appear to be company-specific but may keep PODD on traders’ watchlists. These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
• Negative Sentiment: Multiple law firms announced and promoted securities class action claims against Insulet, with allegations tied to the company’s disclosures and manufacturing controls; this legal overhang can pressure the stock. PODD INVESTOR ALERT: Class Action Lawsuit Filed on Behalf of Insulet Corporation Investors
• Negative Sentiment: The FDA classified Insulet’s Omnipod recall as a Class I recall, the most serious designation, after injury reports, raising concerns about product safety and potential liability. FDA Classifies Insulet Omnipod Recall as Serious After Injury Reports

Wall Street Analyst Weigh In

Several equities analysts have commented on PODD shares. Canaccord Genuity Group lowered their target price on shares of Insulet from $435.00 to $249.00 and set a “buy” rating on the stock in a research report on Thursday, May 7th. Stifel Nicolaus reduced their price target on Insulet from $350.00 to $250.00 in a research report on Thursday, May 7th. Evercore set a $180.00 price target on Insulet in a research note on Monday. Barclays lowered their price objective on Insulet from $286.00 to $198.00 and set an “underweight” rating on the stock in a report on Thursday, May 7th. Finally, Rothschild & Co Redburn reissued a “neutral” rating and issued a $220.00 price objective (down from $380.00) on shares of Insulet in a research note on Friday, April 24th. Twenty-two research analysts have rated the stock with a Buy rating, four have issued a Hold rating and two have issued a Sell rating to the company. According to MarketBeat, Insulet currently has a consensus rating of “Moderate Buy” and an average target price of $237.83.

Insulet Stock Performance

PODD stock traded down $0.54 during mid-day trading on Tuesday, reaching $159.23. 195,897 shares of the stock traded hands, compared to its average volume of 1,245,804. The company has a quick ratio of 1.81, a current ratio of 2.49 and a debt-to-equity ratio of 0.71. Insulet Corporation has a 52 week low of $138.79 and a 52 week high of $354.88. The business has a 50-day moving average of $154.58 and a two-hundred day moving average of $214.47. The firm has a market capitalization of $11.03 billion, a PE ratio of 37.22, a P/E/G ratio of 1.15 and a beta of 1.11.

Insulet (NASDAQ:PODD) last issued its quarterly earnings results on Wednesday, May 6th. The medical instruments supplier reported $1.42 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.19 by $0.23. The company had revenue of $761.70 million for the quarter, compared to the consensus estimate of $729.89 million. Insulet had a return on equity of 26.87% and a net margin of 10.44%.The firm’s revenue was up 33.9% compared to the same quarter last year. During the same period last year, the business posted $1.02 earnings per share. Insulet has set its FY 2026 guidance at 6.210- EPS. As a group, equities analysts predict that Insulet Corporation will post 6.46 EPS for the current fiscal year.

Insiders Place Their Bets

In other Insulet news, Director Timothy C. Stonesifer bought 2,790 shares of the stock in a transaction on Wednesday, June 3rd. The shares were purchased at an average price of $143.51 per share, with a total value of $400,392.90. Following the acquisition, the director directly owned 9,041 shares of the company’s stock, valued at $1,297,473.91. This represents a 44.63% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. 0.36% of the stock is currently owned by insiders.

Insulet Company Profile

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.